BCL2 and pancreatic neoplasm: Nonetheless, pieces of evidence indicate that the “promiscuous” nature (i.e., the capability to interacts with multiple G4 targets) of some G4 ligands [11, 13, 31, 34, 35] may be of therapeutic value, as it has been recently shown for an NDI derivative able to simultaneously target the G4 within BCL2 and KRAS gene promoters in an in vivo model of pancreatic cancer [35].